INTRODUCTION: This study assessed the feasibility, performance, and safety of Mirasol®-treated platelet concentrates (M-PC) stored for up to 7 days. METHODS: This prospective observational study was approved by the ethical committee of the University Clinic of Santiago de Compostela. Informed consent was asked from patients receiving M-PC. M-PCs were treated with the Mirasol system according to the manufacturer's instructions. Thrombocytopenic patients were transfused according to the Spanish transfusion guidelines. Post-transfusion platelet counts were measured at 1 h and/or 24 h after transfusion. Post-transfusion surveillance of patients was maintained during the study. RESULTS: Data from 54 evaluable patients and 135 transfusions were analyzed. The mean age of patients was 58 years. The mean age of M-PC at transfusion was 3.6 days. The mean platelet dose was 3.7 × 1011. The transfusion responses measured as mean corrected count increment 1 h after transfusion (CCI1h) and CCI24h were 9,659 and 4,751, respectively. 65% of transfusions resulted in CCI1h values ≥ 7,500. 51% of transfusions resulted in CCI24h values ≥ 4,500. CONCLUSION: The use of M-PC in the supportive treatment proved to be safe and effective for this cohort of thrombocytopenic patients.
INTRODUCTION: This study assessed the feasibility, performance, and safety of Mirasol®-treated platelet concentrates (M-PC) stored for up to 7 days. METHODS: This prospective observational study was approved by the ethical committee of the University Clinic of Santiago de Compostela. Informed consent was asked from patients receiving M-PC. M-PCs were treated with the Mirasol system according to the manufacturer's instructions. Thrombocytopenicpatients were transfused according to the Spanish transfusion guidelines. Post-transfusion platelet counts were measured at 1 h and/or 24 h after transfusion. Post-transfusion surveillance of patients was maintained during the study. RESULTS: Data from 54 evaluable patients and 135 transfusions were analyzed. The mean age of patients was 58 years. The mean age of M-PC at transfusion was 3.6 days. The mean platelet dose was 3.7 × 1011. The transfusion responses measured as mean corrected count increment 1 h after transfusion (CCI1h) and CCI24h were 9,659 and 4,751, respectively. 65% of transfusions resulted in CCI1h values ≥ 7,500. 51% of transfusions resulted in CCI24h values ≥ 4,500. CONCLUSION: The use of M-PC in the supportive treatment proved to be safe and effective for this cohort of thrombocytopenicpatients.
Authors: Jean-Louis H Kerkhoffs; Wim L J van Putten; Viera M J Novotny; Peter A W Te Boekhorst; Martin R Schipperus; Jaap Jan Zwaginga; Lizzy C M van Pampus; Georgine E de Greef; Marleen Luten; Peter C Huijgens; Anneke Brand; Dick J van Rhenen Journal: Br J Haematol Date: 2010-05-09 Impact factor: 6.998
Authors: Jean-Louis H Kerkhoffs; Jeroen C J Eikenboom; Leo M G van de Watering; Rinie J van Wordragen-Vlaswinkel; Pierre W Wijermans; Anneke Brand Journal: Transfusion Date: 2008-06-28 Impact factor: 3.157
Authors: Joerg-Peter Sigle; Laura Infanti; Jan-Dirk Studt; Maria Martinez; Martin Stern; Alois Gratwohl; Jakob Passweg; André Tichelli; Andreas S Buser Journal: Transfusion Date: 2012-11-26 Impact factor: 3.157
Authors: Americo Cicchetti; Silvia Coretti; Francesco Sacco; Paolo Rebulla; Alessandra Fiore; Filippo Rumi; Rossella Di Bidino; Luz I Urbina; Pietro Refolo; Dario Sacchini; Antonio G Spagnolo; Emanuela Midolo; Giuseppe Marano; Blandina Farina; Ilaria Pati; Eva Veropalumbo; Simonetta Pupella; Giancarlo M Liumbruno Journal: Blood Transfus Date: 2018-09-03 Impact factor: 3.443